Idiopathic Pulmonary Fibrosis Treatment Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2022-27

1
Global Idiopathic Pulmonary Fibrosis Treatment
Market Research and Forecast Report 2022-2027




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Idiopathic Pulmonary Fibrosis Treatment
Market Research Report The latest report by
IMARC Group, titled Idiopathic Pulmonary
Fibrosis Treatment Market Global Industry
Trends, Share, Size, Growth, Opportunity and
Forecast 2022-2027, finds that the global
idiopathic pulmonary fibrosis treatment
market reached a value of US 3,278 Million in
2021. Idiopathic pulmonary fibrosis (IPF) is an
interstitial lung disease that causes scarring of
the lungs, reducing their oxygen delivering
capacity. The chronic lung disease is progressive
and irreversible in nature as it continuously
impacts the functioning of the lungs. It causes
difficulty in breathing and does not provide
sufficient oxygen to different body parts. IPF
can be diagnosed through chest imaging studies,
lung biopsies, pulmonary function tests, and
antibody tests. Thetreatment includes
nintedanib and pirfenidone-based drugs that aid
in lung functioning and minimize the risk of
acute respiratory deterioration. They are also
offered along with oxygen therapy and palliative
care, which improve the chances of recovery and
provide comfort to the patient. Request Free
Sample Report https//www.imarcgroup.com/idiopath
ic-pulmonary-fibrosis-treatment-market/requestsamp
le
4
Report Description and Highlights
Report Description
Global Idiopathic Pulmonary Fibrosis Treatment
Market Trends The market is primarily driven
by the rising geriatric population, which is
susceptible tolung disorders. Aging is considered
the greatest risk factor for the development of
IPF. Moreover, the growing prevalence of fibrotic
diseases, owing to changing lifestyles and heavy
consumption of nicotine products like cigarettes
is also propelling the demand for IPF treatment.
Besides this, major healthcare companies are
extensively investing in the development and
commercialization of novel drugs, especially in
emerging economies, which is fueling the growth
of the market. The rising health consciousness
among individuals regarding effective management
strategies is also creating a positive outlook
for the market. Furthermore, increasing
healthcare expenditures and improving
infrastructure arealso facilitating the market
growth. Looking forward, the market value is
expected to reach US 5,268 Million by 2027,
exhibiting a CAGR of 7.89 during the forecast
period (2022-2027).

5
Report Description and Highlights
Report Description

• Market Summary
• Breakup by Drug Class
• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors
• Breakup by End User
• Hospitals
• Long-term Care Facilities
• Others

6
Report Description and Highlights
Report Description

• Breakup by Region
• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia

7
Report Description and Highlights
Report Description

• Latin America
• Brazil
• Mexico
• Argentina
• Columbia
• Chile
• Peru
• Others
• Middle East and Africa Turkey
• Saudi Arabia
• Iran
• United Arab Emirates
• Others

8
Report Description and Highlights
Report Description

• Competitive Landscape with Key Players
• AdAlta Pty Ltd.
• Angion Biomedica Corp.
• Boehringer Ingelheim International GmbH (C. H.
  Boehringer Sohn AG Co. KG)
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Fibrogen Inc.
• Galapagos NV
• Liminal BioSciences Inc.
• Medicinova Inc.
• Merck Co. Inc.
• Novartis AG
• Vectura Group Plc.
• View Full Report with TOC List of Figure
  https//www.imarcgroup.com/idiopathic-pulmonary-fi
  brosis-treatment-market

9
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
12

Contact Us